Niagen Bioscience is trading at $2.27, down 9.96%, after third-quarter revenue fell 20% year over year. - November 4 results showed revenue of $27.2 million, below analyst expectations, and a $1.2 million net loss. - Management indicated ingredient revenue may finish 2026 below the prior year; positive cash flow and $69.5 million in cash did not offset concerns about weaker sales and outlook. - Shares were live-trading at 9:42 a.m. EST; volume data was not provided.